Cooper Institute for Advanced Reproductive Medicine – FDA 483, Dec 9, 2022
The Cooper Institute for Advanced Reproductive Medicine was cited for multiple deficiencies related to human reproductive tissue establishment operations. The inspection revealed failures in testing oocyte donors for communicable diseases like West Nile Virus, incomplete donor screening questionnaires, and inadequate record retention for HCT/Ps. Additionally, the firm lacked standard operating procedures for handling CMV-positive donors and for overall donor testing, screening, and eligibility determination.
- Inspection date
- December 9, 2022
- Product type
- biologics
ID · 9593851c-8051-4c29-9f1b-122aa7ab233e
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.